**Name of Journal: *World Journal of Cardiology***

**ESPS Manuscript NO: 31907**

**Manuscript Type:** **Minireviews**

**Transcervical access, reversal of flow and mesh-covered stents: New options in the armamentarium of carotid artery stenting**

Paraskevas KI *et al*. Transcervical access, reversal of flow and mesh-covered stents

**Kosmas I Paraskevas, Frank J Veith**

**Kosmas I Paraskevas,** Northern Vascular Centre, Freeman Hospital, Newcastle-upon-Tyne NE7 7DN, United Kingdom

**Frank J Veith,** Divisions of Vascular Surgery, New York University Langone Medical Center, New York, NY 10016, United States

**Frank J Veith,** the Cleveland Clinic, Cleveland, OH 44195, United States

**Author contributions:** Paraskevas KI came up with the idea/topic of the manuscript, searched the literature and wrote the first draft of the manuscript; Veith FJ revised the manuscript and suggested improvements.

**Conflict-of-interest statement:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Kosmas I Paraskevas, MD, PhD,** Northern Vascular Centre, Freeman Hospital, Freeman Road, Newcastle-upon-Tyne NE7 7DN, United Kingdom. [paraskevask@hotmail.com](mailto:paraskevask@hotmail.com)

**Telephone:** +44-73-76104373

**Received:** December 14, 2016

**Peer-review started:** December 16, 2016

**First decision:** January 20, 2017

**Revised:** March 10, 2017

**Accepted:** March 21, 2017

**Article in press:**

**Published online:**

**Abstract**

In the last 25 years, the very existence of carotid artery stenting (CAS) has been threatened on a number of occasions. The initial disappointing results that even lead to the discontinuation of an early randomized controlled trial have improved considerably with time. Novel devices, advanced stent and equipment technology, alternative types of access and several types of filters/emboli protecting devices have been reported to reduce stroke/death rates during/after CAS and improve CAS outcomes. The present review will provide a description of the various technology advances in the field that aim to reduce stroke and death rates associated with CAS. Transcervical access, reversal of flow and mesh-covered stents are currently the most promising tools in the armamentarium of CAS.

**Key words:** Carotid artery stenting; Stroke; Carotid artery stenosis; Filters

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Carotid artery stenting (CAS) has improved considerably in the last few years. This comprehensive review provides the various technology advances in the field that aim to reduce stroke and death rates after CAS. These include transcervical access, reversal of flow and mesh-covered stents.

Paraskevas KI, Veith FJ. Transcervical access, reversal of flow and mesh-covered stents: New options in the armamentarium of carotid artery stenting. *World J Cardiol* 2017; In press

**INTRODUCTION**

During its evolution, carotid artery stenting (CAS) has often gone through some difficult times. One of the first randomized controlled trials comparing CAS with carotid endarterectomy (CEA), the Leicester trial, had to be stopped prematurely after randomizing less than 20 patients[1]. All 10 patients that were randomized to CEA proceeded without complications. On the other hand, 5 of the 7 patients who were randomized to CAS suffered a stroke (*P* = 0.0034), three of which were disabling at 30 d[1].

Fortunately, CAS outcomes have improved considerably since then and continue to improve constantly. Technological advances such as proximal/distal embolic protection devices (EPDs), flow reversal, transcervical/transradial access and double layer mesh stent technology are adjuncts that have been developed to improve CAS outcomes. The current article presents an overview of these technological advances.

**EPDS**

Proximal and distal EPDs are commonly utilized with CAS with the aim of preventing atherosclerotic debris from embolizing to the brain. Catheter manipulation within the aorta and supra-aortic arteries causes plaque embolization. Up to 90% of CAS procedures can be complicated by embolic events and EPDs may capture these embolized particles[2]. Although some studies report good outcomes for various distal EPDs (also known as filtering devices)[3-5], others studies argue that distal filters may not be able to prevent all perioperative emboli[6-9].The pore size of most available filter devices is > 80 μm[3],but many emboli are < 80 μm in size[10,11]. Furthermore, due to the rigidity of many filter devices and a required minimal distal landing zone depending on the length of the basket of the filter device, the vessel wall apposition may not be optimal (especially in tortuous vessel segments) and could therefore allow cerebral embolization[12]. These studies have supported that, compared with distal EPDs, proximal EPDs reduce the perioperative microembolic signals detected by transcranial Doppler and the number of new ischemic lesions[6-9].

A study from Milan, Italy compared the rate of cerebral microembolization during CAS with a proximal EPD (Mo.Ma system [Invatec, Roncadelle, Brescia, Italy]; *n* = 26) versus distal protection with a filter (FilterWire EZ [Boston Scientific Corporation, Santa Clara, California]; *n* = 27) in patients with high-risk, lipid-rich plaques[7]. Compared with use of the FilterWire EZ, the Mo.Ma system significantly reduced mean microembolic signal counts during lesion crossing (mean: 18 *vs* 2, respectively; *P* < 0.0001), stent crossing (mean: 23 *vs* 0, respectively; *P* < 0.0001), stent deployment (mean: 30 *vs* 0, respectively; *P* < 0.0001), stent dilation (mean: 16 *vs* 0, respectively; *P* < 0.0001) and total microembolic signals (mean: 93 *vs* 16, respectively; *P* < 0.0001)[7].

The Mo.Ma proximal EPD is a safe and effective neuroprotection system during CAS that achieves very low periprocedural stroke rates. A registry of 1300 patients undergoing CAS using the Mo.Ma device reported very low major adverse cardiac or cerebrovascular events including 5 deaths (0.38%), 6 major strokes (0.46%), 5 minor strokes (0.38%) and 0 myocardial infarctions (MIs)[13]. The incidence of postprocedural events did not increase even in the presence of theoretical anatomical contraindications to proximal endovascular occlusion (*e.g.,* contralateral carotid occlusion). The excellent results reported for the Mo.Ma device suggest that it is a promising technique for the achievement of low stroke rates after CAS.

A prospective randomized study, the Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting (PROFI) Study, compared the embolic load of filter-protected (*n* = 31) versus proximal balloon-protected CAS (*n* =31)[9]. Proximal balloon occlusion lead to a considerable reduction in the percentage of new cerebral ischemic lesions (45.2% *vs* 87.1%, for proximal balloon occlusion *vs* filter protection, respectively; *P* = 0.001). Proximal balloon occlusion reduced both the number (median [range]: 2 [0-13] *vs* 0 [0-4]; *P* = 0.0001) and the volume (0.47 [0-2.4] cm3 *vs* 0 [0-0.84] cm3; *P* = 0.0001) of new cerebral ischemic lesions. Furthermore, contralateral hemisphere lesions were detected in 29.0% *vs* 6.5% of patients receiving a filter *vs* balloon occlusion, respectively (*P* = 0.047). Finally, the 30-d major adverse cardiovascular and cerebral events rate was 3.2% for filter protection *vs* 0% for balloon occlusion, respectively (*P* = not significant)[9].

A meta-analysis (*n* = 8 studies; 357 patients) evaluated and compared the results of filter cerebral protection *vs* proximal balloon occlusion in preventing embolization during CAS as evaluated by diffusion-weighted magnetic resonance imaging (DW-MRI)[14]. The incidence of new ischemic lesions after CAS/patient detected by DW-MRI (effect size: -0.43; 95%CI: -0.84 to -0.02; I2 = 70.08; Q = 23.40) and the incidence of contralateral site lesions (effect size: -0.50; 95%CI: -0.72 to -0.27; I2 = 0.00; Q = 3.80) were both significantly lower in the proximal balloon occlusion group[14]. The results of this meta-analysis support the superiority of proximal balloon occlusion as compared with filter cerebral protection with respect to the degree of CAS-related brain embolization[14].

Others, however, have supported that proximal EPDs have similar results with distal filter EPD[15].The lack of difference in proximal occlusion versus distal filter EPD results was also verified in a meta-analysis[16].This meta-analysis included 7 studies (*n* = 392 patients; 193 with proximal occlusion; 199 with distal filters). The use of proximal occlusion *vs* distal filter did not reduce the risk of new cerebral lesions (odds ratio [OR]: 0.65; 95% confidence interval [CI]: 0.28-1.52; *P* = 0.32) or the risk of death/cerebrovascular event (OR: 0.59; 95%CI: 0.22-1.60; *P* = 0.30) [16].A more recent meta-analysis verified the equipoise in clinical outcomes between proximal balloon occlusion and distal filter protection[17]. This meta-analysis (*n* = 18 studies; 12281 patients) did not demonstrate any significant difference between the two modalities in terms of the risk of stroke or mortality, nor was there any difference in the incidence of new cerebral lesions on DW-MRI or contralateral DW-MRI lesions. The conclusion reached was that both proximal and distal EPDs provide similar levels of protection from periprocedural stroke and 30-d mortality[17]. Finally, a national cardiovascular data registry analysis from the United States compared stroke/death rates between proximal EPDs and distal filter EPDs in 10,246 consecutive elective CAS procedures. Both EPDs were associated with similar 30-d adverse event rates (2.7% *vs* 4.0%, after proximal *vs* distal filter EPDs, respectively; *P* = 0.22)[18].

**TRANSCERVICAL ACCESS WITH FLOW-REVERSAL**

The first description of flow reversal as a cerebral protection device was in 2000[19].Although initially CAS with flow reversal was performed via the transfemoral approach[19],a subsequent modification was the use of transcervical approach for CAS with flow reversal[20].This technique is described in detail elsewhere[20]. Several independent studies have published very low 30-d stroke/death/MI rates and low incidence of complications for transcervical CAS with flow reversal[21-25]. It was recently demonstrated that transcervical CAS with flow reversal demonstrates embolization rates comparable with CEA[26]. Transcervical CAS with flow reversal thus seems a promising method for the reduction of strokes associated with CAS[27].

Elderly patients (>70 years) have inferior outcomes with transfemoral CAS compared with CEA[28]. The poor outcome of transfemoral CAS in this age group may be explained by the anatomic characteristics of the aortic trunk and supra-aortic vessels as well as by a high prevalence of aortic arch atheromatosis[21]. Transcervical CAS with flow reversal for cerebral protection avoids these unfavorable characteristics. An early study reported a 2.2% 30-d combined stroke/death/MI rates in 219 patients > 70 years of age (55.7% asymptomatic; 44.3% symptomatic)[21]. Symptomatic patients had a 5.1% combined stroke/death/MI rates whereas asymptomatic patients had a 0% rate[21].Thus, transcervical CAS with flow reversal may be the preferred option for this age group.

Not long ago, the Reverse Flow Used During CAS Procedure (ROADSTER) multicenter trial reported its results from the evaluation of the safety and efficacy of the ENROUTE Transcarotid NPS (Silk Road Medical Inc, Sunnyvale, Calif), a novel transcarotid neuroprotection system that provides direct surgical common carotid access and cerebral embolic protection via high-rate flow reversal during CAS[29]. This study reported an overall stroke rate of 1.4%, which is the lowest reported for any prospective multicenter clinical trial of CAS. The stroke/death rates (2.8%) and the stroke/death/MI rates (3.5%) reported were also similarly low[29].

Direct percutaneous carotid access is an alternative access that has been described for CAS. This access can be used in individuals with difficult anatomies, high-risk patients and certain emergent situations that warrant easy and rapid access to the CCA[30]. A systematic review (*n* = 12 studies; 739 CAS procedures) showed that direct CAS with transcervical access (filter protected or unprotected; *n* = 250 patients) and CAS with transcervical access under reversed flow (with arteriovenous shunt in most cases; *n* = 489 patients) are both associated with a low incidence of stroke and complications[31]. The incidence of stroke, MI and death was 1.1%, 0.14% and 0.41%, respectively. The incidence of stroke was 1.2% (3 of 250) in direct CAS with transcervical access and 1.02% (5 of 489) in CAS under reversed flow (*P* = not significant). Transient ischemic attack occurred in 20 patients (2.7%)[31].

**HEAD-TO-HEAD COMPARISON/COMBINATION OF STRATEGIES**

### Several studies have compared/combined the various proposed adjuncts to improve CAS outcomes in an attempt to identify those measures that would help improve CAS results to a greater extent. A study from Argentina compared transradial *vs* transfemoral CAS[32]. A total of 775 consecutive patients undergoing CAS during 16 years were included (101 transradial *vs* 674 transfemoral). The primary combined end-point was in-hospital major adverse cardiac and cerebral events, whereas secondary end-points included angiographic outcome after the procedure and cross-over rate to another puncture site. Angiographic success was achieved in all 775 patients. There was a significant difference in cross-over rate (4.9% *vs* 0%, for the transradial *vs* the transfemoral approach, respectively; *P* < 0.05), but not in the incidence of in-hospital major adverse cardiac and cerebral events (2% *vs* 3.6%, for the transradial *vs* transfemoral approach, respectively; *P* = not significant)[32]. It was concluded that both approaches are safe and efficacious. These results verified the results of an earlier study[33].

### An earlier study from Atlanta, Georgia, United States compared revascularization outcomes after CEA (*n* = 226) *vs* CAS with a distal filter EPD (*n* = 216) *vs* CAS with a proximal flow reversal system (*n* = 53)[34]. The 3 groups did not differ in the overall composite end-point of death, cerebrovascular accident and MI (4% *vs* 5.1% *vs* 0%, respectively; *P* = 0.1) or any individual major adverse event[34].Overall, patients undergoing CAS with EPD had a greater incidence of minor cerebrovascular accidents than CEA patients (6 *vs* 1, or 3.4% *vs* 0.5%, respectively; *P* = 0.031). This was driven by the increased risk for a cerebrovascular accident for asymptomatic patients. Of note, patients undergoing CAS with flow reversal (*n* = 53) had zero adverse events (minor/major stroke, MI or death)[34].

### A study from Japan evaluated the effectiveness of the combined use of distal filter protection device (FilterWire EZ [Boston Scientific, Natick, MA) and the Mo.Ma Ultra (Medtronic, Minneapolis, MN)[35]. The Mo.Ma Ultra is an EPD for interrupting the anterograde blood flow to the internal carotid artery. This study demonstrated that the combined use of a distal filter protection device and Mo.Ma Ultra could provide a more reliable embolic protection in CAS[35].

A study from Italy reported the outcomes of 214 patients undergoing CAS via a transradial (*n* = 154) or a transbrachial (*n* = 60) approach with either the Mo.Ma proximal protection (*n* = 61) or the distal filter protection (*n* = 163)[36]. As a result of technical difficulties in catheterizing the target vessel, crossover to a femoral approach was required in 11 of 153 (7.1%) filter patients, but only in 1 of the 61 (1.6%) Mo.Ma patients. On the other hand, 5 Mo.Ma patients developed acute intolerance to proximal occlusion (4 were subsequently shifted to filter protection). One patient undergoing CAS via the transradial approach was shifted to filter because the Mo.Ma system was too short. Overall, CAS was technically successful in 55 of the 60 (90%) Mo.Ma patients and in 142 of the 154 (93%) filter patients. The 30-d major adverse cardiovascular/cerebrovascular events rate did not differ significantly between the 2 groups (0% for Mo.Ma patients *vs* 2.8% for filter patient; *P* = 0.18). There was similarly no difference in radiation exposure between the 2 groups. Major vascular complications occurred in 1 of the 61 (1.6%) Mo.Ma patients and in 3 of the 153 (1.96%) filter patients, respectively (*P* = 0.18). All these complications occurred during the early learning phase of the transbrachial approach. After a mean follow-up of 8.1 ± 7.5 mo, chronic radial artery occlusion was detected by Doppler ultrasound in 2 of the 30 (6.6%) Mo.Ma patients and by clinical assessment in 4 of 124 (3.2%) filter patients (*P* = 0.25). The conclusion reached was that CAS with proximal protection via a transradial or a transbrachial approach is a safe, feasible and effective technique with low rate of vascular complications[36].

A study from Japan compared the effectiveness of the embolization prevention mechanism of 2 types of EPDs - a distal protection balloon (*n* = 82 patients) and a distal protection filter (*n* = 82 patients)[37]. Positive findings on postoperative diffusion-weighted imaging were found in more patients with distal protection balloon compared with the distal protection filter (34 *vs* 22 patients, or 41.4% *vs* 26.8%, respectively). Furthermore, in the distal protection balloon group there were more strokes than in the distal protection filter group (2 minor and 2 major strokes *vs* 0 strokes, respectively)[37].A combination of flow reversal and distal filter may be more effective than either modality alone[38].

Controversial results were reported in a small study from Brazil[39].This study compared flow reversal *vs* filter protection in 40 patients undergoing CAS using a femoral approach. Compared with flow reversal (*n* = 21), filter protection (*n* = 19) resulted in a reduction in the incidence (15.8% *vs* 47.6%, respectively; *P* = 0.03), number (0.73 *vs* 2.6, respectively; *P* = 0.05) and size (0.81 *vs* 2.23 mm, respectively; *P* = 0.05) of new ischemic brain lesions[39]. Flow reversal was associated with a tendency toward increased incidence of ipsilateral ischemic lesions more than those who had filter protection (70% *vs* 0.0%, respectively; *P* = 0.07). In addition, flow reversal showed a greater tendency toward increased incidence of ipsilateral lesions than bilateral (70% *vs* 30%, respectively; *P* = 0.07)[39].As the authors mentioned, this trial was the first to show better results using filter protection than a proximal protective technique during CAS. The authors attributed these good results to their considerable operator experience with CAS, the general anesthesia (which minimized the risk of movement accidents) and to the filter protection device profile[39].

**ADVANCES WITH STENT DESIGN**

#### Several important advances in stent design have also lead to improved CAS outcomes. For instance, the Inspire MD technology (Tel Aviv, Israel) includes a bare-metal stent (Inspire MD C-Guard stent) covered by a micron level mesh (MicroNet). Preliminary results appear encouraging[40].A prospective multicenter study, the C-Guard CARotid Embolic protection using microNET (CARENET) trial evaluated the feasibility of the C-Guard carotid embolic protective stent system[41]. This is a novel thin-strut nitinol stent combined with a polyethylene terephthalate mesh covering. This study reported a 0%3 0-d major adverse cardiac or cerebrovascular events rate in 30 patients[41].Another stent that has demonstrated promising results is the double-layer CASPER-RX stent[42].Finally, the Roadsaver Micromesh stent is a novel nitinol double-layer micromesh stent. Preliminary results from high-volume centres showing a low incidence of embolic events and new ipsilateral ischemic brain lesions are encouraging[43,44].

#### During CAS, debris is often trapped in stent interstices. When flow is restored following CAS, the trapped debris may prolapse through the stent struts and result in delayed cerebral embolization[45]. Three companies (RoadsaverTM Micromesh Carotid Stent, Terumo, Japan; C-GuardTM MicroNet-Covered Embolic Prevention Stent System, InspireMD, Boston, MA, United States; and Scaffold Stent, W.L. Gore & Associates, Flagstaff, AZ, United States) are evaluating membrane or mesh covered carotid stents with smaller interstices to prevent such delayed strokes[45].

The advances in carotid stent material and the new types of stents introduced in the market are beyond the scope of this review and are more extensively described elsewhere[46].

**CONCLUSION**

The battle for CAS is not lost[47]. The long-term results of the Carotid Revascularization Endarterectomy versus Stenting Trial did not show a significant difference in periprocedural stroke, MI or death and subsequent ipsilateral stroke between symptomatic and asymptomatic patients undergoing CAS or CEA[48] Similarly, the Asymptomatic Carotid Trial demonstrated non-inferiority for CAS compared with CEA for asymptomatic patients with respect to the primary composite end-point of 30-d death, stroke or MI and ipsilateral stroke within 1 year[49]. New devices, membrane- and mesh-covered stents, alternative approaches and a combination of EPDs are tools in the armamentarium of CAS to improve its results. There is more to see in the future and we will all be awaiting the results of new trials incorporating the advances in CAS technology.

**REFERENCES**

1. **Naylor AR**, Bolia A, Abbott RJ, Pye IF, Smith J, Lennard N, Lloyd AJ, London NJ, Bell PR. Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. *J Vasc Surg* 1998; **28**: 326-334 [PMID: 9719328 DOI: 10.1016/S0741-5214(98)70182-X]
2. **Ledwoch J**, Staubach S, Segerer M, Strohm H, Mudra H. Incidence and risk factors of embolized particles in carotid artery stenting and association with clinical outcome. *Int J Cardiol* 2017; **227**: 550-555 [PMID: 27829527 DOI: 10.1016/j.ijcard.2016.10.103]
3. **Hornung M**, Franke J, Bertog SC, Gafoor S, Grunwald I, Sievert H. Initial Experience Using the Gore Embolic Filter in Carotid Interventions. *J Invasive Cardiol* 2016; **28**: 334-339 [PMID: 27466274]
4. **Nii K**, Tsutsumi M, Maeda H, Aikawa H, Inoue R, Eto A, Sakamoto K, Mitsutake T, Hanada H, Kazekawa K. Comparison of Flow Impairment during Carotid Artery Stenting Using Two Types of Eccentric Filter Embolic Protection Devices. *Neurol Med Chir* (Tokyo) 2016; **56**: 759-765 [PMID: 27319302 DOI: 10.2176/nmc.oa.2016-0036]
5. **Iko M**, Aikawa H, Go Y, Nakai K, Tsutsumi M, Yu I, Mizokami T, Sakamoto K, Inoue R, Mitsutake T, Eto A, Hanada H, Kazekawa K. Treatment outcomes of carotid artery stenting with two types of distal protection filter device. *Springerplus* 2014; **3**: 132 [PMID: 25674435 DOI: 10.1186/2193-1801-3-132]
6. **Atchaneeyasakul K**, Khandelwal P, Ambekar S, Ramdas K, Guada L, Yavagal D. Safety Outcomes Using a Proximal Protection Device in Carotid Stenting of Long Carotid Stenoses. *Interv Neurol* 2016; **5**: 123-130 [PMID: 27781040 DOI: 10.1159/000447022]
7. **Montorsi P**, Caputi L, Galli S, Ciceri E, Ballerini G, Agrifoglio M, Ravagnani P, Trabattoni D, Pontone G, Fabbiocchi F, Loaldi A, Parati E, Andreini D, Veglia F, Bartorelli AL. Microembolization during carotid artery stenting in patients with high-risk, lipid-rich plaque. A randomized trial of proximal versus distal cerebral protection. *J Am Coll Cardiol* 2011; **58**: 1656-1663 [PMID: 21982309 DOI: 10.1016/j.jacc.2011.07.015]
8. **Schmidt A**, Diederich KW, Scheinert S, Bräunlich S, Olenburger T, Biamino G, Schuler G, Scheinert D. Effect of two different neuroprotection systems on microembolization during carotid artery stenting. *J Am Coll Cardiol* 2004; **44**: 1966-1969 [PMID: 15542277 DOI: 10.1016/j.jacc.2004.08.049]
9. **Bijuklic K**, Wandler A, Hazizi F, Schofer J. The PROFI study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting): a prospective randomized trial. *J Am Coll Cardiol* 2012; **59**: 1383-1389 [PMID: 22284330 DOI: 10.1016/j.jacc.2011.11.035]
10. **Moody DM**, Bell MA, Challa VR, Johnston WE, Prough DS. Brain microemboli during cardiac surgery or aortography. *Ann Neurol* 1990; **28**: 477-486 [PMID: 2252360 DOI: 10.1002/ana.410280403]
11. **Rapp JH**, Pan XM, Sharp FR, Shah DM, Wille GA, Velez PM, Troyer A, Higashida RT, Saloner D. Atheroemboli to the brain: size threshold for causing acute neuronal cell death. *J Vasc Surg* 2000; **32**: 68-76 [PMID: 10876208 DOI: 10.1067/mva.2000.107315]
12. **Coggia M**, Goëau-Brissonnière O, Duval JL, Leschi JP, Letort M, Nagel MD. Embolic risk of the different stages of carotid bifurcation balloon angioplasty: an experimental study. *J Vasc Surg* 2000; **31**: 550-557 [PMID: 10709069 DOI: 10.1067/mva.2000.102730]
13. **Stabile E**, Salemme L, Sorropago G, Tesorio T, Nammas W, Miranda M, Popusoi G, Cioppa A, Ambrosini V, Cota L, Petroni G, Della Pietra G, Ausania A, Fontanelli A, Biamino G, Rubino P. Proximal endovascular occlusion for carotid artery stenting: results from a prospective registry of 1,300 patients. *J Am Coll Cardiol* 2010; **55**: 1661-1667 [PMID: 20394868 DOI: 10.1016/j.jacc.2009.11.079]
14. **Stabile E**, Sannino A, Schiattarella GG, Gargiulo G, Toscano E, Brevetti L, Scudiero F, Giugliano G, Perrino C, Trimarco B, Esposito G. Cerebral embolic lesions detected with diffusion-weighted magnetic resonance imaging following carotid artery stenting: a meta-analysis of 8 studies comparing filter cerebral protection and proximal balloon occlusion. *JACC Cardiovasc Interv* 2014; **7**: 1177-1183 [PMID: 25240544 DOI: 10.1016/j.jcin.2014.05.019]
15. **Mokin M**, Dumont TM, Chi JM, Mangan CJ, Kass-Hout T, Sorkin GC, Snyder KV, Hopkins LN, Siddiqui AH, Levy EI. Proximal versus distal protection during carotid artery stenting: analysis of the two treatment approaches and associated clinical outcomes. *World Neurosurg* 2014; **81**: 543-548 [PMID: 24355517 DOI: 10.1016/j.wneu.2013.10.031]
16. **Cassese S**, Ndrepepa G, King LA, Nerad M, Schunkert H, Kastrati A, Ott I, Fusaro M. Proximal occlusion versus distal filter for cerebral protection during carotid stenting: updated meta-analysis of randomised and observational MRI studies. *EuroIntervention* 2015; **11**: 238-246 [PMID: 25735933 DOI: 10.4244/EIJY15M03\_01]
17. **Omran J**, Mahmud E, White CJ, Aronow HD, Drachman DE, Gray W, Abdullah O, Abu-Fadel M, Firwana B, Mishkel G, Al-Dadah AS. Proximal balloon occlusion versus distal filter protection in carotid artery stenting: A meta-analysis and review of the literature. *Catheter Cardiovasc Interv* 2016 Nov 12; Epub ahead of print [PMID: 27862881 DOI: 10.1002/ccd.26842]
18. **Giri J**, Parikh SA, Kennedy KF, Weinberg I, Donaldson C, Hawkins BM, McCormick DJ, Jackson B, Armstrong EJ, Ramchand P, White CJ, Jaff MR, Rosenfield K, Yeh RW. Proximal versus distal embolic protection for carotid artery stenting: a national cardiovascular data registry analysis. *JACC Cardiovasc Interv* 2015; **8**: 609-615 [PMID: 25907088 DOI: 10.1016/j.jcin.2015.02.001]
19. **Parodi JC**, La Mura R, Ferreira LM, Mendez MV, Cersósimo H, Schönholz C, Garelli G. Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices. *J Vasc Surg* 2000; **32**: 1127-1136 [PMID: 11107084 DOI: 10.1067/mva.2000.109209]
20. **Criado E**, Doblas M, Fontcuberta J, Orgaz A, Flores A. Transcervical carotid artery angioplasty and stenting with carotid flow reversal: surgical technique. *Ann Vasc Surg* 2004; **18**: 257-261 [PMID: 15253268 DOI: 10.1007/s10016-004-0018-5]
21. **Alvarez B**, Matas M, Ribo M, Maeso J, Yugueros X, Alvarez-Sabin J. Transcervical carotid stenting with flow reversal is a safe technique for high-risk patients older than 70 years. *J Vasc Surg* 2012; **55**: 978-984 [PMID: 22322116 DOI: 10.1016/j.jvs.2011.10.084]
22. **Chang DW**, Schubart PJ, Veith FJ, Zarins CK. A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention. *J Vasc Surg* 2004; **39**: 994-1002 [PMID: 15111851 DOI: 10.1016/j.jvs.2004.01.045]
23. **Pinter L**, Ribo M, Loh C, Lane B, Roberts T, Chou TM, Kolvenbach RR. Safety and feasibility of a novel transcervical access neuroprotection system for carotid artery stenting in the PROOF Study. *J Vasc Surg* 2011; **54**: 1317-1323 [PMID: 21658889 DOI: 10.1016/j.jvs.2011.04.040]
24. **Leal I**, Orgaz A, Flores Á, Gil J, Rodríguez R, Peinado J, Criado E, Doblas M. A diffusion-weighted magnetic resonance imaging-based study of transcervical carotid stenting with flow reversal versus transfemoral filter protection. *J Vasc Surg* 2012; **56**: 1585-1590 [PMID: 22960021 DOI: 10.1016/j.jvs.2012.05.107]
25. **Goode SD**, Hoggard N, Macdonald S, Evans DH, Cleveland TJ, Gaines PA. Assessment of reverse flow as a means of cerebral protection during carotid artery stent placement with diffusion-weighted and transcranial Doppler imaging. *J Vasc Interv Radiol* 2013; **24**: 528-533 [PMID: 23462063 DOI: 10.1016/j.jvir.2012.12.014]
26. **Plessers M**, Van Herzeele I, Hemelsoet D, Patel N, Chung EM, Vingerhoets G, Vermassen F. Transcervical Carotid Stenting With Dynamic Flow Reversal Demonstrates Embolization Rates Comparable to Carotid Endarterectomy. *J Endovasc Ther* 2016; **23**: 249-254 [PMID: 26794908 DOI: 10.1177/1526602815626561]
27. **Paraskevas KI**, Veith FJ, Parodi JC. Commentary: Transcervical Carotid Artery Stenting (CAS) With Flow Reversal: A Promising Technique for the Reduction of Strokes Associated With CAS. *J Endovasc Ther* 2016; **23**: 255-257 [PMID: 26984815 DOI: 10.1177/1526602816633830]
28. **Voeks JH**, Howard G, Roubin GS, Malas MB, Cohen DJ, Sternbergh WC, Aronow HD, Eskandari MK, Sheffet AJ, Lal BK, Meschia JF, Brott TG. Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. *Stroke* 2011; **42**: 3484-3490 [PMID: 21980205 DOI: 10.1161/STROKEAHA.111.624155]
29. **Kwolek CJ**, Jaff MR, Leal JI, Hopkins LN, Shah RM, Hanover TM, Macdonald S, Cambria RP. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. *J Vasc Surg* 2015; **62**: 1227-1234 [PMID: 26506270 DOI: 10.1016/j.jvs.2015.04.460]
30. **Bergeron P**. Direct percutaneous carotid access for carotid angioplasty and stenting. *J Endovasc Ther* 2015; **22**: 135-138 [PMID: 25775694 DOI: 10.1177/1526602814564362]
31. **Sfyroeras GS**, Moulakakis KG, Markatis F, Antonopoulos CN, Antoniou GA, Kakisis JD, Brountzos EN, Liapis CD. Results of carotid artery stenting with transcervical access. *J Vasc Surg* 2013; **58**: 1402-1407 [PMID: 24074938 DOI: 10.1016/j.jvs.2013.07.111]
32. **Mendiz OA**, Fava C, Lev G, Caponi G, Valdivieso L. Transradial Versus Transfemoral Carotid Artery Stenting: A 16-Year Single-Center Experience. *J Interv Cardiol* 2016; **29**: 588-593 [PMID: 27634206 DOI: 10.1111/joic.12342]
33. **Ruzsa Z**, Nemes B, Pintér L, Berta B, Tóth K, Teleki B, Nardai S, Jambrik Z, Szabó G, Kolvenbach R, Hüttl K, Merkely B. A randomised comparison of transradial and transfemoral approach for carotid artery stenting: RADCAR (RADial access for CARotid artery stenting) study. *EuroIntervention* 2014; **10**: 381-391 [PMID: 25042266 DOI: 10.4244/EIJV10I3A64]
34. **Brewster LP**, Beaulieu R, Corriere MA, Veeraswamy R, Niazi KA, Robertson G, Dodson TF, Kasirajan K. Carotid revascularization outcomes comparing distal filters, flow reversal, and endarterectomy. *J Vasc Surg* 2011; **54**: 1000-104; discussion 1000-104; [PMID: 21871772 DOI: 10.1016/j.jvs.2011.03.279]
35. **Moteki Y**, Niimi Y, Sato S, Inoue T, Shima S, Okada Y. Effectiveness of the Combined Use of Distal Filter Protection Device and Mo.Ma Ultra: Technical Note. *J Stroke Cerebrovasc Dis* 2016; **25**: 2627-2631 [PMID: 27476338 DOI: 10.1016/j.strokecerebrovascdis.2016.07.003]
36. **Montorsi P**, Galli S, Ravagnani PM, Tresoldi S, Teruzzi G, Caputi L, Trabattoni D, Fabbiocchi F, Calligaris G, Grancini L, Lualdi A, de Martini S, Bartorelli AL. Carotid Artery Stenting With Proximal Embolic Protection via a Transradial or Transbrachial Approach: Pushing the Boundaries of the Technique While Maintaining Safety and Efficacy. *J Endovasc Ther* 2016; **23**: 549-560 [PMID: 27270761 DOI: 10.1177/1526602816651424]
37. **Iko M**, Tsutsumi M, Aikawa H, Matsumoto Y, Go Y, Nii K, Abe G, Ye I, Nomoto Y, Kazekawa K. Distal protection filter device efficacy with carotid artery stenting: comparison between a distal protection filter and a distal protection balloon. *Jpn J Radiol* 2013; **31**: 45-49 [PMID: 23179785 DOI: 10.1007/s11604-012-0145-9]
38. **Harada K**, Kakumoto K, Morioka J, Saito T, Fukuyama K. Combination of flow reversal and distal filter for cerebral protection during carotid artery stenting. *Ann Vasc Surg* 2014; **28**: 651-658 [PMID: 24378246 DOI: 10.1016/j.avsg.2013.04.032]
39. **Castro-Afonso LH**, Abud LG, Rolo JG, Santos AC, Oliveira Ld, Barreira CM, Velasco TR, Pontes-Neto OM, Abud DG. Flow reversal versus filter protection: a pilot carotid artery stenting randomized trial. *Circ Cardiovasc Interv* 2013; **6**: 552-559 [PMID: 24084627 DOI: 10.1161/CIRCINTERVENTIONS.113.000479]
40. **Mazzaccaro D**, Occhiuto MT, Righini P, Malacrida G, Nano G. Initial experience with the inspire MD C-Guard stent in the treatment of carotid artery disease. *J Cardiovasc Surg* (Torino) 2016; **57**: 474-478 [PMID: 27094426]
41. **Schofer J**, Musiałek P, Bijuklic K, Kolvenbach R, Trystula M, Siudak Z, Sievert H. A Prospective, Multicenter Study of a Novel Mesh-Covered Carotid Stent: The CGuard CARENET Trial (Carotid Embolic Protection Using MicroNet). *JACC Cardiovasc Interv* 2015; **8**: 1229-1234 [PMID: 26292586 DOI: 10.1016/j.jcin.2015.04.016]
42. **Wissgott C**, Schmidt W, Brandt C, Behrens P, Andresen R. Preliminary Clinical Results and Mechanical Behavior of a New Double-Layer Carotid Stent. *J Endovasc Ther* 2015; **22**: 634-639 [PMID: 26187981 DOI: 10.1177/1526602815593490]
43. **Nerla R**, Castriota F, Micari A, Sbarzaglia P, Secco GG, Ruffino MA, de Donato G, Setacci C, Cremonesi A. Carotid artery stenting with a new-generation double-mesh stent in three high-volume Italian centres: clinical results of a multidisciplinary approach. *EuroIntervention* 2016; **12**: e677-e683 [PMID: 27497367 DOI: 10.4244/EIJV12I5A109]
44. **Ruffino MA**, Faletti R, Bergamasco L, Fonio P, Righi D. Incidence of New Ischaemic Brain Lesions After Carotid Artery Stenting with the Micromesh Roadsaver Carotid Artery Stent: A Prospective Single-Centre Study. *Cardiovasc Intervent Radiol* 2016; **39**: 1541-1549 [PMID: 27571985 DOI: 10.1007/s00270-016-1454-7]
45. **Cremonesi A**, Castriota F, Secco GG, Macdonald S, Roffi M. Carotid artery stenting: an update. *Eur Heart J* 2015; **36**: 13-21 [PMID: 25535085 DOI: 10.1093/eurheartj/ehu446]
46. **He D**, Liu W, Zhang T. The development of carotid stent material. *Interv Neurol* 2015; **3**: 67-77 [PMID: 26019710 DOI: 10.1159/000369480]
47. **Paraskevas KI**, Veith FJ. Techniques and innovations to improve carotid artery stenting outcomes. *Int J Cardiol* 2016; **222**: 986-987 [PMID: 27526376 DOI: 10.1016/j.ijcard.2016.08.148]
48. **Brott TG**, Howard G, Roubin GS, Meschia JF, Mackey A, Brooks W, Moore WS, Hill MD, Mantese VA, Clark WM, Timaran CH, Heck D, Leimgruber PP, Sheffet AJ, Howard VJ, Chaturvedi S, Lal BK, Voeks JH, Hobson RW. Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis. *N Engl J Med* 2016; **374**: 1021-1031 [PMID: 26890472 DOI: 10.1056/NEJMoa1505215]
49. **Rosenfield K**, Matsumura JS, Chaturvedi S, Riles T, Ansel GM, Metzger DC, Wechsler L, Jaff MR, Gray W. Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. *N Engl J Med* 2016; **374**: 1011-1020 [PMID: 26886419 DOI: 10.1056/NEJMoa1515706]

**P-Reviewer:** Jiang XJ, Setacci C, Tomassini F **S-Editor:** Kong JX **L-Editor: E-Editor:**